Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

C-reactive protein does not diagnose nonalcoholic steatohepatitis

C-reactive protein is increased in both liver and adipose tissue in obese patients independently from non-alcoholic steatohepatitis, report doctors in this month's American Journal of Gastroenterology.

News image

fiogf49gjkf04

C-reactive protein is a nonspecific marker of inflammation that is moderately elevated in obesity, metabolic, and type 2 diabetes.

It has been proposed as a surrogate marker of nonalcoholic steatohepatitis.

Dr Rodolphe Anty and colleagues from France evaluated its clinical usefulness in the diagnosis of nonalcoholic steatohepatitis in severely obese patients.

The patients were without or withmetabolic syndrome, diabetes, and nonalcoholic steatohepatitis.

The team of doctors characterized the potential roles of the liver and of the adipose tissue in C-reactive protein production.

The team studied 13 severely obese patients without nonalcoholic steatohepatitis and without metabolic syndrome, and 11 with with metabolic syndrome.

The doctors studied a further 7 with metabolic syndrome and diabetes and 15 with nonalcoholic steatohepatitis.

Of those with non-alcoholic steatohepatitis, 8 were without and 7 with metabolic syndrome.

For each patient, the team collected liver and adipose tissue biopsies during a bariatric surgery and were used to determine the C-reactive protein gene expression.

C-reactive protein mRNA levels were positively correlated with those of interleukin-6
American Journal of Gastroenterology

The role of interleukin-6 and lipopolysaccharide in C-reactive protein expression was also evaluated in subcutaneous adipose tissue obtained during cosmetic abdominoplasty.

The doctors elevated plasma C-reactive protein levels in severely obese patients independently of metabolic syndrome, diabetes, or nonalcoholic steatohepatitis.

The team found that C-reactive protein gene expression was not only increased in livers but also in adipose tissues of obese patients compared with controls subjects.

In human adipose tissue, C-reactive protein mRNA levels were positively correlated with those of interleukin-6.

The team observed that the C-reactive protein expression was enhanced in vitro by interleukin-6 and lipopolysaccharide.

Dr Anty's team concluded, “Plasma C-reactive protein levels are not predictive of the diagnosis of nonalcoholic steatohepatitis in severely obese patients.”

“The liver as well as the adipose tissue can produce C-reactive protein, a process which could be dependent on interleukin-6.”

“Therefore, both tissues might contribute to the elevated plasma C-reactive protein levels found in obesity.”

“In addition, the large amount of body fat may well produce an important part of the circulating C-reactive protein, further limiting its clinical usefulness in the evaluation of nonalcoholic steatohepatitis in severely obese patients.”

Am J Gastroenterol 2006: 101(8): 1824
15 August 2006

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us